EX-10.1 2 dex101.htm DEVELOPMENT, OPTION AND LICENSE AGREEMENT DEVELOPMENT, OPTION AND LICENSE AGREEMENTDevelopment, Option and License Agreement • May 5th, 2020
THIS DEVELOPMENT, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 15th day of May, 2003 (the “Effective Date”), by and between POZEN INC., a Delaware corporation, located at 1414 Raleigh Road, Suite 400, Chapel Hill, NC 27517 on behalf of itself and its Affiliates (collectively “POZEN”), and NYCOMED DANMARK APS, a Danish corporation, located at Langebjerg 1, DK-4000 Roskilde, Denmark on behalf of itself and its Affiliates (collectively “Nycomed”). POZEN and Nycomed are referred to in this Agreement individually as a “Party” and collectively as “Parties.”
DEVELOPMENT, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC INTERNATIONAL HOLDING LTDDevelopment, Option and License Agreement • May 9th, 2012 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This DEVELOPMENT, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 3rd day of January, 2012 (the “Effective Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and BIOGEN IDEC INTERNATIONAL HOLDING LTD, a Bermuda limited company, having its principal place of business at Canon’s Court, 22 Victoria Street, Hamilton HM12 Bermuda (“Biogen Idec”). Biogen Idec and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement.
DEVELOPMENT, OPTION AND LICENSE AGREEMENTDevelopment, Option and License Agreement • January 11th, 2006 • Pozen Inc /Nc • Pharmaceutical preparations
THIS SUPPLY AGREEMENT (the “Agreement”) is entered into as of the day of , (the “Effective Date”), by and between NYCOMED DANMARK APS, a Danish corporation, located at Langebjerg 1, DK-4000 Roskilde, Denmark, on behalf of itself and its Affiliates (collectively, “Nycomed”), and , a corporation, located at , on behalf of itself and its Affiliates (collectively, “Buyer”). Nycomed and the Buyer are referred to in this Agreement individually as a “Party” and collectively as “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Development, Option and License Agreement • October 18th, 2021 • Allarity Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS DEVELOPMENT, OPTION AND LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of the 1st day of March, 2019 (the “Effective Date”)
